Business
NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen Lab
Calgary, Alberta--(Newsfile Corp. - July 19, 2022) - NurExone Biologic Inc.  (TSXV: NRX)&...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen LabCalgary, Alberta--(Newsfile Corp. - July 19, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (\"CNS\") indications, announced the signing of a Material Transfer Agreement (the \"Agreement\") dated July 18th, 2022 with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (\"Yissum\"), the wholly-owned subsidiary and technology transfer company of the Hebrew University of Jerusalem (the \"Hebrew University\").The Agreement relates to the transfer of certain biological, chemical, and other tangible materials (the \"Materials\") to Yissum for use by Prof. Tal Burstyn-Cohen and her team at the Hebrew University. Prof Burstyn-Cohen is an experienced researcher at the Hebrew University and leader of the Burstyn-Cohen Lab which researches molecular and cellular mechanisms that underlie tissue homeostasis in health. The Materials will be used to evaluate compositions and methods to enhance the cellular uptake of particles and organelles by small molecules, in accordance with the mutually agreed research plan attached to the Agreement. Specifically, Prof. Burstyn-Cohen's work will involve the coating of exosomes with a specialized molecule and evaluating the uptake of the coated exosomes in an inflamed brain mouse model. Under the Agreement, NurExone will have an option to receive an exclusive license to the jointly owned results and related intellectual property (if any) that may arise from the research by Prof. Burstyn-Cohen, in the field of neurodegenerative diseases and CNS indications.Results of the collaboration may be the basis of publications in scientific journals, manuscripts, book chapters or at any scientific conferences or meetings subject to NurExone's right of review in accordance with the terms of the Agreement. According to Dr. Lior Shaltiel, CEO of NurExone, \"As a pioneer of ExoTherapy, NurExone's goal is to establish leadership in the field of human mesenchymal-derived exosome production and loading of therapeutic molecules into exosomes. To advance the science, awareness...